Prebiotics for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03987126|
Recruitment Status : Not yet recruiting
First Posted : June 14, 2019
Last Update Posted : June 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injuries Neurogenic Bowel Bladder Dysfunction||Dietary Supplement: Human Milk Oligosaccharides (HMO) Other: Placebo||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||One placebo arm and one active treatment arm, participants will be assigned to each arm equally based on their Neurogenic Bowel Dysfunction score.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||No other parties will be masked for the study. A part of the study will be open label.|
|Official Title:||Use of Novel Human Milk Prebiotics to Improve the Quality of Life for Spinal Cord Injury Patients With Bowel and Bladder Dysfunction|
|Estimated Study Start Date :||August 2019|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2020|
Active Comparator: Human Milk Oligosaccharide (HMO)
10 g sachet, self-administered for 3 months.
2'-O-fucosyllactose and lacto-N-neotetraose, novel human milk oligosaccharide (HMO) sugars have already been shown to very specifically modulate intestinal bacteria, namely the beneficially viewed bifidobacteria, in clinical studies in adults. Modulating bifidobacteria increases the levels of specific short chain fatty acids (SCFAs), such as butyrate, propionate and acetate.These SCFAs have been shown to stimulate colonic sodium and fluid absorption and exert proliferative effects on the colonocyte in experimental animal studies since the 1990s (Scheppach 1994). Therefore, increasing their levels would lead to an improvement in intestinal motility, as has been summarised previously (Koh 2016)
Dietary Supplement: Human Milk Oligosaccharides (HMO)
Sachet containing 10 grams of HMO
Placebo Comparator: Placebo
10 g sachet, self-administered for 3 months.
Placebo sachets are identical to the HMO sachets in color, taste, smell, size and shape
Sachet manufactured to mimic 10g of HMO
Other Name: Placebo for HMO
- Bowel motility [ Time Frame: 12 weeks ]Improvement of 25-30% in our study population in the neurogenic bowel function of our intervention study group after treatment, will be measured by the Neurogenic Bowel dysfunction score. Neurogenic Bowel Dysfunction score will be measured by a symptom-based questionnaire that scores 10 variables to attain a total score between 0 and 47. It includes frequency of bowel movements, time of defecation, evacuation and incontinence.
- Neurogenic bowel dysfunction score (NBD) [ Time Frame: 12 weeks ]The change in this assessment from baseline to end of study will help determine the improvement in bowel motility. It is a symptom-based questionnaire that scores 10 variables to attain a total score between 0 and 47. It includes frequency of bowel movements, time of defecation, evacuation and incontinence.
- Change in method of bowel assistance [ Time Frame: 12 weeks ]Medications required, home remedies used, other methods of assistance will be recorded in a study questionnaire.
- Duration of bowel routine [ Time Frame: 12 weeks ]Measured by the NBD questionnaire.
- Episodes of incontinence [ Time Frame: 12 weeks ]Will be measured in time between bowel movements by the NBD questionnaire.
- Frequency of bowel movements per week [ Time Frame: 12 weeks ]Will be measured by the NBD questionnaire.
- Microbiome changes from baseline to end of study [ Time Frame: 12 weeks ]Changes in the entire bacterial community from baseline to end of study will be assessed in the lab from faecal and urine samples collected by the participant. The microbes may vary by participant and the study will be looking at which ones present themselves in each case. Of particular interest may be the Enterobacteriaceae like Escherichia coli that cause UTI. Units of measure via culture are colony forming units per g (cfu/g).
- Changes in pain [ Time Frame: 12 weeks ]A modified International Spinal Cord Injury Pain Basic Dataset version 2.0 questionnaire will be used. The first part of the questionnaire is a scale that ranges from 1-10, with 1 stating their pain is not interfering with their daily activities, and 10 stating extreme interference. The second part is a table that lists different areas of the body and has the participant check off whether they feel pain in the right, middle, or left side of each body area. Pain type will be assessed by the referring clinician and documented in a study CRF.
- Change in sleep [ Time Frame: 12 weeks ]will be documented in the International Spinal Cord Injury Pain Basic Dataset v2.0 questionnaire. The question scales from 1 - 10, 1 stating that pain has had no interference with the participant getting a good night's sleep, and 10 stating major interference.
- Change in mood [ Time Frame: 12 weeks ]will be documented in the International Spinal Cord Injury Pain Basic Dataset v2.0 questionnaire. The answer will be measured in a scale from 1-10, 1 stating that pain has had no interference with their mood, and 10 stating major interference.
- Quality of Life Measures survey [ Time Frame: 12 weeks ]a general quality of life measures survey will be included in the study. The QOLS is scored by adding up the score on each item to yield a total score for the instrument. The cale includes 16 questions, each question can be answered from a range of 1-7 (1 being very unhappy, 7 being very happy) Scores can range from 16 to 112.
- Number of participants reporting unexpected adverse events [ Time Frame: 12 weeks ]Adverse events will be recorded through case report forms and reported to the principal investigator. Side effects will be assessed using standardized case report forms at each visit. Participants are encouraged to contact the coordinator to report any concerns.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03987126
|Contact: Alexandria Roa Agudelo||519-646-6100 ext 42696||Alexandria.RoaAgudelo@sjhc.london.on.ca|
|Contact: Jeremy P Burton, PhD||519-646-6000 ext 61365||Jeremy.Burton@LawsonResearch.Com|
|Parkwood Institute||Not yet recruiting|
|London, Ontario, Canada, N6C0A7|
|Contact: Alexandria Roa Agudelo, MLA/T 519-646-6100 ext 42696 Alexandria.RoaAgudelo@sjhc.london.on.ca|
|Contact: Eldon Loh, MD 519-685-4080 Eldon.Loh@sjhc.london.on.ca|
|Principal Investigator:||Jeremy P Burton, PhD||Lawson Health Research Institute|